Advances in the development of new vaccines against tuberculosis. 100 years after the introduction of BCG

Journal Title: Advances in Hygiene and Experimental Medicine - Year 2014, Vol 68, Issue

Abstract

The BCG vaccine used in the world for nearly 100 years protects children against the most severe forms of tuberculosis, but its effectiveness in preventing the most commonly occurring tuberculosis and the one burdened with the highest risk of transmission in adults is very diverse. Contraindications for BCG vaccination include HIV infection and other conditions of immunosuppression. Tuberculosis is a global problem difficult to control because of three main reasons: poor diagnostics in developing countries, long-term therapy or discontinuation of treatment resulting in the emergence of drug-resistant mycobacteria, and the availability of a TB vaccine which only protects children from the most severe forms of tuberculosis. BCG has little to no efficacy in preventing the most common adult pulmonary TB. The development of a more effective vaccine against tuberculosis is undoubtedly still a public health priority in order to improve control of the disease throughout the world. Elimination of TB as a global public health goal by 2050 is particularly ambitious and its achievement depends on the development and application of new intervention measures and newly designed vaccines. Currently, 14 newly developed products are undergoing clinical trials. These include a prophylactic vaccine capable of replacing the current BCG, booster vaccines to increase the effects of BCG, and therapeutic vaccines. The aim of the study is to present the current state of knowledge on cutting-edge research into new vaccines against tuberculosis, their efficacy, immunogenicity and potential use in the future.

Authors and Affiliations

Katarzyna Krysztopa-Grzybowska, Anna Lutyńska

Keywords

Related Articles

Effects of lactoferrin on elicitation of the antigen-specific cellular and humoral cutaneous response in mice

Immune contact dermatitis is an inflammation of the skin resulting from exposure to allergens in the environment. The aim of this study was to compare the actions of lactoferrin (LF), a natural immunomodulator, on the el...

The frequency of myeloid and lymphoid dendritic cells in multiple myeloma patients is inversely correlated with disease progression

Multiple myeloma (MM) is a neoplastic disease characterized by proliferation and prolonged survival of clonal plasma cells, most frequently occurring in the bone marrow, but also in other tissues. Dendritic cells (DCs) a...

Antioxidant and antimicrobial properties of bioactive phytochemicals from cranberry

In the rational human diet, the important role of fruits and vegetables, which are a source of bioactive phytochemicals, is emphasized. Among fruits particular attention, due to a number of documented health-promoting pr...

Mitochondria w niedotlenieniu mózgu

Neurony różnią się znacznie kształtem, rozmiarem, rodzajem neuroprzekaźników i liczbą tworzonych synaps. Ich wspólną cechą charakterystyczną jest bardzo duża wrażliwość na zmiany stężenia tlenu. Następstwem niedotlenieni...

The current state of research on psychiatric genetics in Poland and the world: A report covering recent years

The aim of this article was to review the results of research carried out in recent years in relation to genetic studies in psychiatry. The authors’ focus is on the selected disorders, with particular emphasis on the rep...

Download PDF file
  • EP ID EP67409
  • DOI -
  • Views 119
  • Downloads 0

How To Cite

Katarzyna Krysztopa-Grzybowska, Anna Lutyńska (2014). Advances in the development of new vaccines against tuberculosis. 100 years after the introduction of BCG. Advances in Hygiene and Experimental Medicine, 68(), 768-776. https://europub.co.uk/articles/-A-67409